<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27870" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Protamine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Applefield</surname>
            <given-names>Daniel</given-names>
          </name>
          <aff>Wayne St. University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Krishnan</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Wayne St. University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Applefield declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Krishnan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27870.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Protamine is a medication used to reverse and neutralize the anticoagulant effects of heparin. Protamine is the specific antagonist that neutralizes heparin-induced anticoagulation. Protamine is a strongly alkaline (nearly two-thirds of the amino acid composition is arginine) polycationic low-molecular-weight protein found in salmon sperm that is also currently available in a recombinant form. This activity reviews indications, contraindications, mechanisms of action, adverse event profile, and other key elements of protamine use that are pertinent for members of the interprofessional team that manage the care of patients who require reversal of heparin.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of administration of protamine.</p></list-item><list-item><p>Describe the adverse effects of protamine administration.</p></list-item><list-item><p>Summarize the appropriate monitoring necessary when administering protamine.</p></list-item><list-item><p>Discuss the importance of collaboration and communication amongst the interprofessional team to improve outcomes for patients receiving protamine in the cardiac operating room setting.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27870&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27870">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27870.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Protamine is an FDA-approved drug for use in neutralizing the effect of unfractionated heparin.<xref ref-type="bibr" rid="article-27870.r1">[1]</xref><xref ref-type="bibr" rid="article-27870.r2">[2]</xref> It is most commonly used to neutralize heparin-induced anticoagulation after separation from cardiopulmonary bypass. When appropriately dosed, this neutralization reduces the risk of postoperative bleeding.<xref ref-type="bibr" rid="article-27870.r3">[3]</xref>&#x000a0;Protamine is also utilized to reverse the anticoagulation effects of unfractionated heparin in the setting of dialysis, invasive vascular procedures, and acute ischemic strokes.<xref ref-type="bibr" rid="article-27870.r4">[4]</xref>&#x000a0;Finally, clinicians can use protamine for a partial reversal of low molecular weight heparins, including enoxaparin, dalteparin, and tinzaparin, but the degree of reversal is unclear, and this use has not been FDA-approved.<xref ref-type="bibr" rid="article-27870.r2">[2]</xref>&#x000a0;Currently, protamine is produced using recombinant technology, but it was originally isolated from salmon fish sperm.<xref ref-type="bibr" rid="article-27870.r3">[3]</xref>&#x000a0;When first introduced, protamine was used to prolong the action of insulin preparations; adding it to the preparation prolonged the duration of action of the insulin and delayed insulin absorption.<xref ref-type="bibr" rid="article-27870.r5">[5]</xref><xref ref-type="bibr" rid="article-27870.r3">[3]</xref></p>
      </sec>
      <sec id="article-27870.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Unfractionated heparin is a strongly anionic anticoagulant that forms a salt aggregate when exposed to the positive cationic arginine peptide of protamine.<xref ref-type="bibr" rid="article-27870.r6">[6]</xref> The salt aggregate that forms is inactive and has no anticoagulant properties. Protamine has a rapid onset of action, neutralizes unfractionated heparin within 5 minutes, and has a relatively short half-life of approximately 10 minutes.&#x000a0;There is very little known about the metabolism of the heparin-protamine salt aggregate. Some studies have described the metabolism of the salt in the liver, while other studies have reported that the salt is metabolized and excreted by the kidneys.<xref ref-type="bibr" rid="article-27870.r7">[7]</xref><xref ref-type="bibr" rid="article-27870.r8">[8]</xref>&#x000a0;Care is necessary to administer the proper dose of protamine, as excessive doses, protamine has been shown to possess anticoagulation properties and may cause bleeding and increased transfusion requirements.<xref ref-type="bibr" rid="article-27870.r3">[3]</xref><xref ref-type="bibr" rid="article-27870.r9">[9]</xref></p>
      </sec>
      <sec id="article-27870.s4" sec-type="Administration">
        <title>Administration</title>
        <p>In the cardiac operating room setting, protamine is typically administered intravenously as an infusion over 10 to 15 minutes; this slow infusion is intended to decrease the likelihood of side effects that can occur if infused too rapidly. Many anesthesiologists in the cardiac operating room setting will administer a small bolus of protamine, often called a "test dose," to allow for early detection of adverse reactions, including hemodynamic instability. Often, protamine is administered through a peripheral intravenous line rather than a central line, as studies have shown that protamine delivered through a&#x000a0;central line can cause an increase in plasma histamine levels and a decrease in systemic vascular resistance.<xref ref-type="bibr" rid="article-27870.r10">[10]</xref>&#x000a0;If no adverse reaction occurs, then the balance of the protamine dose is infused. Proper dosing of protamine to reverse heparin is controversial and varies in the medical literature.<xref ref-type="bibr" rid="article-27870.r3">[3]</xref></p>
        <p>Protamine is packaged as an intravenous solution in a concentration of 10 milligrams/milliliter. To neutralize heparin, 1 to 1.5 mg of protamine gets injected per 100 units of heparin. Initial protamine treatment for dalteparin, tinzaparin, or enoxaparin overdosage is 1 mg protamine per 100 units of the low molecular weight heparin given. Follow-up doses of protamine in the 0.5 mg range per 100 units can be given if bleeding continues 4 hours later. The efficacy of protamine reversing heparin can be assessed by measuring the activated clotting time or performing a thromboelastogram test. In clinical trials, hemodynamic changes and arterial oxygenation changes decreased with protamine infusion via the ascending aorta vs. a central venous line suggesting this may be the preferred route of administration.<xref ref-type="bibr" rid="article-27870.r11">[11]</xref></p>
      </sec>
      <sec id="article-27870.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effect associated with protamine administration includes an anaphylactic response consisting of systemic hypotension, pulmonary vasoconstriction, allergic reactions, pulmonary hypertension, bronchoconstriction, and bradycardia. The incidence of anaphylactic reactions ranges from 0.06% to 10.6%.<xref ref-type="bibr" rid="article-27870.r9">[9]</xref> There are also reports of liver and kidney tissue damage.<xref ref-type="bibr" rid="article-27870.r6">[6]</xref>&#x000a0;Suspected anaphylactic responses to protamine receive treatment in the same way, other perioperative anaphylactic reactions. Therapies include the use of albuterol, methylprednisolone, H1, and H2 antihistamines, vasopressin, norepinephrine, fluid administration, glucagon, and echocardiography to monitor cardiac function.&#x000a0;</p>
        <p>Excess protamine can also negatively impact platelet function, interfere with coagulation factors, and stimulate the breakdown of the clot.<xref ref-type="bibr" rid="article-27870.r3">[3]</xref> The thinking is that protamine may potentiate fibrinolysis by decreasing thrombin concentrations.<xref ref-type="bibr" rid="article-27870.r3">[3]</xref>&#x000a0;</p>
        <p>Pulmonary hypertension is a potentially catastrophic adverse response to protamine administration; it is believed to be due to thromboxane A2 release. This release of thromboxane has been shown in studies to increase pulmonary vascular resistance by up to 10 times.<xref ref-type="bibr" rid="article-27870.r12">[12]</xref><xref ref-type="bibr" rid="article-27870.r13">[13]</xref>&#x000a0;This condition can have treatment with the use of a prostacyclin EI infusion. Some studies have suggested the protamine-induced pulmonary hypertension is preventable by continuing aspirin intake before surgery, as aspirin suppresses the production of thromboxanes through its irreversible inactivation of the cyclooxygenase enzyme.</p>
        <p>Hypotension from protamine infusion is thought to be due to intracellular calcium release and nitric oxide release.<xref ref-type="bibr" rid="article-27870.r14">[14]</xref><xref ref-type="bibr" rid="article-27870.r15">[15]</xref>&#x000a0;Prevention options include antihistamines to suppress an allergic response and steroids to reduce any inflammatory response.<xref ref-type="bibr" rid="article-27870.r5">[5]</xref>&#x000a0;Vasopressors are often used to counteract protamine-induced hypotension.</p>
      </sec>
      <sec id="article-27870.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients with a history of past protamine exposure, vasectomy, fish allergies, and insulin-controlled diabetes are at increased risk of an adverse reaction.<xref ref-type="bibr" rid="article-27870.r16">[16]</xref><xref ref-type="bibr" rid="article-27870.r3">[3]</xref><xref ref-type="bibr" rid="article-27870.r17">[17]</xref><xref ref-type="bibr" rid="article-27870.r18">[18]</xref>&#x000a0;The patients most common patients at risk for a protamine reaction were on&#x000a0;NPH insulin in the past. There are approximately 2.8 milligrams of protamine per 100 units of protamine zinc insulin and 0.5 milligrams of protamine per 100 units of isophane (NPH) insulin. Presumably, chronic exposure to low doses of protamine in a patient on these insulin preparations can cause the formation of antibodies to protamine.&#x000a0;</p>
      </sec>
      <sec id="article-27870.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Protamine should be given slowly, and patients should be monitored closely for anaphylaxis, rapid hypotension, or an increase in pulmonary artery pressures.&#x000a0; Anaphylaxis can cause an&#x000a0;increase in peak airway pressures along with hypotension, a rash, and wheezing, or difficulty breathing. The presence of an arterial line for invasive blood pressure monitoring and/or a pulmonary artery catheter to monitor changes in pulmonary artery pressures is advantageous to recognize early negative sequelae from protamine administration. It is also imperative for the medical staff to have access to cardiovascular rescue drugs (vasoactive/inotropic drugs) and resuscitation equipment should an adverse reaction occur.</p>
      </sec>
      <sec id="article-27870.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Protamine&#x02019;s toxicity is thought to be due to its positive charge. It has been shown to cause a decrease in endothelial cell ATP production and progressive mitochondrial injury in bovine pulmonary endothelial cells.<xref ref-type="bibr" rid="article-27870.r19">[19]</xref> Protamine also has a toxic effect on myocardial cells, postulated to be due to its positive charge affecting mitochondrial cells intracellularly.<xref ref-type="bibr" rid="article-27870.r20">[20]</xref> The theory is that the salt formed between protamine and heparin that effectively neutralizes the positively charged molecule of protamine offers some intracellular protection against toxicity.</p>
      </sec>
      <sec id="article-27870.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The use of protamine requires an interprofessional team of healthcare professionals that includes physicians, nurses, and cardiac perfusionists. Without proper management and communication, the morbidity and mortality from protamine can be high. In cardiac surgery, protamine administration must be communicated to all healthcare team members, as protamine administration before separation from cardiopulmonary bypass can be fatal. Typically after separation from cardiopulmonary bypass, the cardiac surgeon asks for protamine to be given to reverse the effects of heparin. This request should be followed by closed-loop communication from the anesthesiologist that the protamine infusion has begun. This is to inform the cardiac perfusionists to stop all suction devices that drain into the cardiopulmonary bypass machine (to avoid introducing protamine into the cardiopulmonary bypass circuit in the event that the patient needs to be put back on cardiopulmonary bypass), as well as to inform the cardiac surgeon and nursing staff in the room to be vigilant for adverse reactions.</p>
        <p>Protamine is useful in several different clinical scenarios in the hospital setting. The proper dosing and speed of infusion or injection of protamine to neutralize the anticoagulant effects of heparin should be appropriately followed. In other clinical situations, physicians and nursing should be extremely vigilant in monitoring patients for adverse reactions. Appropriate resources should be available to monitor and treat patients who experience adverse effects due to its administration. An understanding of the appropriate laboratory tests to follow during its administration is also critical to the safe use of protamine.</p>
        <p>For decades since the start of cardiac surgery using cardiopulmonary bypass, investigators have studied the methods to provide a safe, efficient, and reproducible way of performing complex cardiac surgeries. Advances in cardiopulmonary bypass result from evidence-based randomized controlled trials, cohort studies, and anecdotal practice or consensus. After reviewing all available evidence, in 2018, The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of Extra-corporeal Technology released their clinical practice guidelines for anticoagulation during cardiopulmonary bypass. These guidelines discussed the use of heparin as the primary anticoagulant (bivalirudin if there are heparin contraindications) and protamine as the reversal agent.<xref ref-type="bibr" rid="article-27870.r21">[21]</xref>&#x000a0;Though there are ongoing investigations into new medications for anticoagulation and reversal of such anticoagulation, the current gold standards for anticoagulation and reversal of anticoagulation for cardiac surgery continue to be heparin and protamine.<xref ref-type="bibr" rid="article-27870.r22">[22]</xref></p>
        <p>Protamine is a medication that requires the collaborative efforts of an interprofessional team, including clinicians, surgeons, anesthesiologists, nurse anesthetists, nursing, and pharmacists. As mentioned above, proper preparation, dosing, and protocol are necessary when using protamine, and each member of the team has the role to play in the bigger picture. Nursing should be monitoring along with anesthesia personnel. The pharmacist should have verified the planned dosing along with the heparin used for the procedure. Clinicians need to seek input and feedback from these other members so that the interprofessional team actually functions as such, not with everyone siloed into their own discipline. This approach will lead to proper protamine use and better patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-27870.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27870&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27870">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27870/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27870">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27870.s11">
        <title>References</title>
        <ref id="article-27870.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carr</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The heparin-protamine interaction. A review.</article-title>
            <source>J Cardiovasc Surg (Torino)</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>659</fpage>
            <page-range>659-66</page-range>
            <pub-id pub-id-type="pmid">10596998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holzmacher</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sarani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Indications and Methods of Anticoagulation Reversal.</article-title>
            <source>Surg Clin North Am</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>97</volume>
            <issue>6</issue>
            <fpage>1291</fpage>
            <page-range>1291-1305</page-range>
            <pub-id pub-id-type="pmid">29132510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meesters</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Veerhoek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vonk</surname>
                <given-names>ABA</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review.</article-title>
            <source>Br J Anaesth</source>
            <year>2018</year>
            <month>May</month>
            <volume>120</volume>
            <issue>5</issue>
            <fpage>914</fpage>
            <page-range>914-927</page-range>
            <pub-id pub-id-type="pmid">29661409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ranasinghe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mays</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Quedado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Adcock</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Thrombolysis Following Heparin Reversal With Protamine Sulfate in Acute Ischemic Stroke: Case Series and Literature Review.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>104283</fpage>
            <pub-id pub-id-type="pmid">31324409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nybo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Madsen</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Serious anaphylactic reactions due to protamine sulfate: a systematic literature review.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-6</page-range>
            <pub-id pub-id-type="pmid">18816305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokolowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kalaska</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miklosz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mogielnicki</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The toxicology of heparin reversal with protamine: past, present and future.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>897</fpage>
            <page-range>897-909</page-range>
            <pub-id pub-id-type="pmid">27223896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stehle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wunder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinn</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schrenk</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Friedrich</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Dempfle</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Maier-Borst</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Heene</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats.</article-title>
            <source>J Surg Res</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-204</page-range>
            <pub-id pub-id-type="pmid">7861773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeLucia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wakefield</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Kadell</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wrobleski</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>VanDort</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stanley</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Tissue distribution, circulating half-life, and excretion of intravenously administered protamine sulfate.</article-title>
            <source>ASAIO J</source>
            <year>1993</year>
            <season>Jul-Sep</season>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>M715</fpage>
            <page-range>M715-8</page-range>
            <pub-id pub-id-type="pmid">8268631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kimmel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Sekeres</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ellison</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass.</article-title>
            <source>Anesth Analg</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>94</volume>
            <issue>6</issue>
            <fpage>1402</fpage>
            <page-range>1402-8, table of contents</page-range>
            <pub-id pub-id-type="pmid">12031996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casthely</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fyman</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Aaron</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Hemodynamic changes after the administration of protamine.</article-title>
            <source>Anesth Analg</source>
            <year>1986</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>78</fpage>
            <page-range>78-80</page-range>
            <pub-id pub-id-type="pmid">3940472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaney</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Devin Roberts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wroblewski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shahul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaudet</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jeevanandam</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Protamine Administration Via the Ascending Aorta May Prevent Cardiopulmonary Instability.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>647</fpage>
            <page-range>647-55</page-range>
            <pub-id pub-id-type="pmid">26948466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morel</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nguyenduy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Repine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Chenoweth</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Zapol</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep. Evidence for the role of reactive oxygen metabolites following nonimmunological complement activation.</article-title>
            <source>Circ Res</source>
            <year>1988</year>
            <month>May</month>
            <volume>62</volume>
            <issue>5</issue>
            <fpage>905</fpage>
            <page-range>905-15</page-range>
            <pub-id pub-id-type="pmid">3129208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horiguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Enzan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mitsuhata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Heparin-protamine complexes cause pulmonary hypertension in goats.</article-title>
            <source>Anesthesiology</source>
            <year>1995</year>
            <month>Oct</month>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>786</fpage>
            <page-range>786-91</page-range>
            <pub-id pub-id-type="pmid">7574058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murase</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Naruse</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okumura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hayakawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sokabe</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Protamine augments stretch induced calcium increase in vascular endothelium.</article-title>
            <source>Br J Pharmacol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>134</volume>
            <issue>7</issue>
            <fpage>1403</fpage>
            <page-range>1403-10</page-range>
            <pub-id pub-id-type="pmid">11724745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pevni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gurevich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frolkis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Keren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shapira</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Paz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Locker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Protamine induces vasorelaxation of human internal thoracic artery by endothelial NO-synthase pathway.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>2050</fpage>
            <page-range>2050-3</page-range>
            <pub-id pub-id-type="pmid">11156119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiler</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gellhaus</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Hottel</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Schillig</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Vegh</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>85</volume>
            <issue>4</issue>
            <fpage>713</fpage>
            <page-range>713-9</page-range>
            <pub-id pub-id-type="pmid">2182695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srivastava</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Saravanan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Successful on-pump coronary artery bypass without using protamine.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>91</volume>
            <issue>2</issue>
            <fpage>608</fpage>
            <page-range>608-10</page-range>
            <pub-id pub-id-type="pmid">21256330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knape</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>de Haan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bovill</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>An anaphylactic reaction to protamine in a patient allergic to fish.</article-title>
            <source>Anesthesiology</source>
            <year>1981</year>
            <month>Sep</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>324</fpage>
            <page-range>324-5</page-range>
            <pub-id pub-id-type="pmid">7270957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wakefield</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Hinshaw</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Burkel</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Stanley</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Protamine-induced reductions of endothelial cell ATP.</article-title>
            <source>Surgery</source>
            <year>1989</year>
            <month>Aug</month>
            <volume>106</volume>
            <issue>2</issue>
            <fpage>378</fpage>
            <page-range>378-85</page-range>
            <pub-id pub-id-type="pmid">2763036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kossekova</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Mitovska</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Dancheva</surname>
                <given-names>KI</given-names>
              </name>
            </person-group>
            <article-title>Protamine inhibition of the oxidative phosphorylation in intact, cytochrome c-depleted and restored mitochondria.</article-title>
            <source>Acta Biol Med Ger</source>
            <year>1975</year>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>539</fpage>
            <page-range>539-47</page-range>
            <pub-id pub-id-type="pmid">171893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shore-Lesserson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ferraris</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Greilich</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hammon</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass.</article-title>
            <source>Anesth Analg</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>126</volume>
            <issue>2</issue>
            <fpage>413</fpage>
            <page-range>413-424</page-range>
            <pub-id pub-id-type="pmid">29346209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27870.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouraghda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gillois</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Albaladejo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Alternatives to heparin and protamine anticoagulation for cardiopulmonary bypass in cardiac surgery].</article-title>
            <source>Can J Anaesth</source>
            <year>2015</year>
            <month>May</month>
            <volume>62</volume>
            <issue>5</issue>
            <fpage>518</fpage>
            <page-range>518-28</page-range>
            <pub-id pub-id-type="pmid">25697279</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
